

Communication

Single cell 'Glucose Nanosensor' verifies elevated glucose levels in individual cancer cells

Raphael A.S. Nascimento, Rifat Emrah Ozel, Wai Han Mak, Marcelo Mulato, Bakthan Singaram, and Nader Pourmand

Nano Lett., **Just Accepted Manuscript** • DOI: 10.1021/acs.nanolett.5b04495 • Publication Date (Web): 11 Jan 2016

Downloaded from <http://pubs.acs.org> on January 13, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications

Nano Letters is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Single cell ‘Glucose Nanosensor’ verifies elevated glucose levels in individual cancer cells

Raphael A. S. Nascimento^{‡,1,2}, Rıfat Emrah Özel^{‡,1}, Wai Han Mak¹, Marcelo Mulato^{1,2}, Bakthan Singaram³, and Nader Pourmand^{1*}

¹Biomolecular Engineering Department, University of California Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA

²Department of Physics, Faculty of Philosophy, Science and Letters at Ribeirão Preto, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14040-401, Brazil

³Department of Chemistry and Biochemistry, University of California Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA

* To whom correspondence should be addressed:

Nader Pourmand, Ph.D.

Biomolecular Engineering Department, University of California Santa Cruz


1156 High Street, Santa Cruz, 95064

Tel: +1-831-502-7315, Fax: +1-831-459-2891

Email: Pourmand@soe.ucsc.edu

[‡] R.A.S.N. and R.E.O. contributed equally.

Graphical Abstract



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Because the transition from oxidative phosphorylation to anaerobic glycolytic metabolism is a hallmark of cancer progression, approaches to identify single living cancer cells by their unique glucose metabolic signature would be useful. Here we present nanopipettes specifically developed to measure glucose levels in single cells with temporal and spatial resolution, and we use this technology to verify the hypothesis that individual cancer cells can indeed display higher intracellular glucose levels. The nanopipettes were functionalized as glucose nanosensors by immobilizing Glucose Oxidase (GOx) covalently to the tip so that the interaction of glucose with GOx resulted in a catalytic oxidation of β -D-glucose to D-gluconic acid, which was measured as a change in impedance due to drop in pH of the medium at the nanopipette tip. Calibration studies showed a direct relationship between impedance changes at the tip and glucose concentration in solution. The glucose nanosensor quantified single cell intracellular glucose levels in human fibroblasts and the metastatic breast cancer lines MDA-MB-231 and MCF7 and revealed that the cancer cells expressed reproducible and reliable increases in glucose levels compared to the non-malignant cells. Nanopipettes allow repeated sampling of the same cell, as cells remain viable during and after measurements. Therefore nanopipette-based glucose sensors provide an approach to compare changes in glucose levels with changes in proliferative or metastatic state. The platform has great promise for mechanistic investigations, as a diagnostic tool to distinguish cancer cells from non-malignant cells in heterogeneous tissue biopsies, as well as a tool for monitoring cancer progression in situ.

Keywords: Biosensor, Intracellular Glucose, Cancer Metabolomics, Single Cell, Nanopore, Nanopipette

1 All cells require glucose for survival but, because of their rapid growth and proliferation,
2 tumor cells require increased metabolic activity compared to non-proliferating cells. Cancer
3 cells are known to alter their metabolic pathways by shifting from mitochondrial oxidative
4 phosphorylation to anaerobic glycolysis under hypoxic conditions. The latter is an energetically
5 inefficient process that requires excess amounts of glucose.¹⁻³ Cancer cells can adapt to the
6 increased requirement for glucose by increasing expression of glucose transporters GLUT1 and
7 GLUT12.⁴⁻⁶ The transition of cancer cells to the glycolysis pathway confers protection against
8 apoptosis, prolongs survival, increases proliferation and enhances resistance against
9 chemotherapeutic drugs.⁷⁻⁹ There is also an association between metabolism and virulence:
10 oncogenic viruses enhance glucose uptake in infected cells by affecting expression of glucose
11 transporters, such as GLUT 1 and GLUT2, as well as glycolytic enzymes.¹⁰

12 While a number of studies have suggested that glucose metabolism in cancerous cells is
13 altered, and there is speculation that metastatic and drug-resistant behavior might be a result of
14 this altered metabolism, little is known about the intracellular glucose concentration at single cell
15 level.¹¹ Identification of individual cancer cells with high intracellular glucose levels in a
16 population is of great importance to study transcriptomic and genomic differences of such cells,
17 as they can provide specific targets for new generation cancer therapies.

18 Because the transition from oxidative phosphorylation to anaerobic glycolytic metabolism
19 occurs at the single cell level and is a hallmark of cancer progression, we sought an approach to
20 identify individual living cancer cells by their unique metabolic signatures. Such an approach
21 would have important uses in monitoring cancer progression, and could have implications in
22 cancer diagnostics in searching for malignant cells in tissue biopsies. A single-cell approach
23 could also facilitate the development of novel therapies to block cancer cell progression or

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 selectively kill cancerous cells at early stages of development, and the search for drugs that
2 overcome cancer cell resistance.

3 Current technologies to investigate cancer biology at the single-cell level utilize indirect (*e.g.*
4 microdialysis, nuclear magnetic resonance (NMR) fluorescence spectroscopy, *etc.*) or destructive
5 experimental approaches, and do not allow investigation of an intact single cancer cell
6 metabolism due to low sensitivity and selectivity with low spatial resolution.^{12, 13} Furthermore,
7 differentiation between non-cancerous and cancerous cells in a heterogeneous tumor tissue
8 based on metabolic activities is not possible with conventional methods. Standard biochemical
9 approaches and metabolomics techniques disrupt and homogenize the heterogeneous tissue,
10 preventing resolution of glucose utilization in the relative small population of cancer cells.¹⁴
11 Fluorescence probes have been widely used to study single cell metabolism.^{15, 16} Other
12 approaches have been employed that require 2-photon microscopy; this, however, can involve
13 photobleaching of tagged glucose, which may not behave like natural glucose.^{17, 18} Notably, most
14 of these probes have been designed for research purposes to be used on homogeneous cell lines.
15 Additionally, little is known about the impact of these probes on regular cell metabolism.
16 Consequently, they cannot be utilized to perform differential glucose measurements in cancer
17 cells versus non-cancer cells in heterogeneous cell populations like those found in tumors.
18 Recently, the use of electrochemical microsensors ($> 0.7 \mu\text{m}$) has been demonstrated for
19 intracellular glucose measurement in frog oocytes and human adipocytes.¹⁹ Both models are
20 examples of large spherical cell types with diameters bigger than $60 \mu\text{m}$. However, most
21 adherent human cells, including cancerous cells, fall within a size range of $10\text{-}20 \mu\text{m}$ in diameter
22 and 0.5 to $3 \mu\text{m}$ in thickness.^{20, 21} Therefore, manual insertion of such microsensors in adherent

1 cells is difficult; moreover, the damage inflicted upon the cells due to the relatively large probe
2 size may cause inaccurate assessment of intracellular metabolites.

3 Intracellular investigation at the single-cell level is challenging due to the lack of (i) non-
4 destructive analytical sensors and (ii) controlled cell targeting technology. To address the
5 shortcomings of the current methods for single-cell measurements, we have developed a novel
6 sensing technology taking advantage of an emerging nanotechnology based on the use of
7 nanopipettes.²² The nanopipette tip is <100 nm, 1/10th the size of a standard micropipette used
8 for patch clamp electrophysiology.²³ Due to the small pore diameter, the nanopipette can be
9 inserted into single cells repetitively without altering cellular functions.²⁴ The small size of the
10 nanopipette tip provides high spatial resolution, and allows site- and target-specific insertion and
11 measurement of metabolic activities at single-cell level in a heterogeneous cell population.^{25, 26}
12 Additionally, nanopipette sensors provide real-time intracellular measurements by taking
13 advantage of scanning ion conductance microscopy (SICM) principles.²⁷⁻²⁹ We have shown
14 previously that nanopipette tips can be coated with biorecognition materials such as antibodies,
15 aptamers and chelating agents that selectively bind to specific cellular targets.^{23, 30, 31} A current is
16 passed through the nanopipette, and the current changes when antigen binds to the antibody at
17 the tip. The impedance change can be used for detection of target molecules with high
18 sensitivity. In this paper, we describe the fabrication of a nanobiosensor to perform direct
19 measurement of free glucose at the single-cell level. We demonstrate that the nanopipette
20 technology successfully distinguishes single breast cancer cells from single non-malignant
21 human cells based on their glucose levels. Our technology can therefore be applied to diagnostic
22 and mechanistic studies of cancer, and would also be applicable to other investigations of
23 metabolic heterogeneity in a cell population.

1 To adapt our nanopipettes into glucose nanosensors, we developed a targeting system for the
2 nanopipette with a custom-built SICM setup²⁶ (Supporting Information (SI) **Figure S1**). This
3 device allows the automated positioning of the nanopipette tip nanometers above a target cell.
4 The SICM can be used to insert the nanopipette inside a target cell and then automatically
5 reposition the nanopipette tip, once extracted from the cell, at the same position in the same cell
6 for continuous monitoring of an individual cell over time.

7 Quartz nanopipette surfaces are negatively charged at human physiological pH. Poly-l-lysine
8 (PLL), a polycationic molecule, is used to functionalize the inner wall of the nanopipette through
9 electrostatic interactions and hydrogen bonds. Additionally, amino groups on the PLL backbone
10 provide functionalities where further modification can be performed. To facilitate glucose
11 oxidase immobilization, the nanopipette surface was activated with glutaraldehyde, which
12 crosslinks the enzyme to the PLL modified surface (**Figure 1A**). .

13 The operational principle of the nanopipette is based on the changes in ionic current at the
14 functionalized tip. This change is called current rectification. A negative surface charge results in
15 high current response at negative applied potentials whereas a positively charged surface shows
16 high current response at positive potential. Taking advantage of this principle, surface properties
17 after each modification step were characterized using linear sweep voltammetry in a potential
18 range from -1 to 1 V at a scan rate of 0.1 V/s (**Figure 1B**). Bare quartz surface is negatively
19 charged at physiological pH conditions, thus the voltammetric trace is also negatively rectified
20 (black line). After the poly-l-lysine modification, the ionic current at positive potentials increased
21 significantly. This rectification bias is due to the protonated amino residues at PLL backbone
22 (red line). Glutaraldehyde treatment decreases the positive charge at the surface as it binds to
23 PLL (green line). After the glucose oxidase functionalization, the nanopipette displayed a

1 significant negative rectification because GOx contains negative charge at physiological pH
2 (blue line). Scanning electron micrographs were taken to demonstrate the tip geometry and to
3 calculate the pore opening of nanopipettes. SEM images showed that the nanopipette pore was
4 circular and its size was between 90 – 100 nm (**Figure 1C**).

5 The glucose sensing principle of a GOx-functionalized nanopipette is based on the catalytic
6 oxidation of β -D-glucose to D-gluconolactone and hydrogen peroxide (**Figure 1D**). As a part of
7 the cellular respiration, cells convert, through phosphorylation processes, glucose into glucose-6-
8 phosphate, which cannot undergo enzymatic reaction with glucose oxidase.³²⁻³⁴ Therefore
9 glucose oxidase is used commonly to determine free glucose levels in bodily fluids. GOx is a
10 homodimer containing its cofactor flavin adenine dinucleotide (FAD) bound to its two identical
11 80-kDa subunits. Two simultaneous processes contribute to the concentration-dependent ionic
12 current changes at the nanopipette. The first is the GOx-catalyzed oxidation of D-glucose
13 producing gluconic acid, through the spontaneous hydrolysis of the initial product
14 gluconolactone, that proportionately reduces the pH at the nanopore. The second is the second
15 generation glucose biosensor like effect. Hydrogen peroxide is the byproduct of enzymatic
16 reaction and can involve a redox reaction with ferrocene, an electron mediator.³⁵ The control
17 experiments conducted in the absence of ferrocene did not show high sensitivity towards glucose
18 (data is not shown) proving evidence that the total ionic current change is a combination of local
19 pH change and redox processes.

Figure 1

21 **Figure 2** represents the potential-response changes during the controlled cell finding and
22 intracellular measurements are performed. It is worthy to note that the first and third parts of the
23 x-axis are presented in distance. The distance given (~25 μ m) in **Figure 2** demonstrates the

relative travel distance of the nanosensors between its origin point and cell surface. During the cell finding protocol a fixed potential of 500 mV is applied (experimental details are given in supporting information). When current-clamp signal was recorded at 1 nA during the surface finding to compare with the intracellular measurements, a steady state potential response has been observed suggesting that the potential was not affected from the locational changes of the nanosensor. When the nanosensor is in close proximity to a cell, alteration in the electrical signal initiates computerized cell penetration (Figure S5). Experimentally, the minimum penetration depth is found to be 0.8 μm . When the nanotip penetrates into a target cell, potential-response of the glucose-functionalized nanosensor changes due to the intracellular glucose level. Typical recordings in the cell last for 60 sec. After the nanosensor is extracted from the cell, the tip potential found to be similar to the baseline levels recorded prior to the insertion. This fact indicates the tip is intact and insertion protocol does not damage the glucose nanosensors, and also provides evidence that the nanopipette resistance changes only when the glucose oxidase reacts with free glucose at the nanopore. The cell surface finding and penetration signal are shown in detail in Figure S5 in the supporting information. These data demonstrate that a single glucose nanosensor can be reutilized for multiple cell interrogations.

Figure 2

Current-clamp technique which is utilized regularly in our lab has been selected for the determination of glucose oxidase modified quartz nanopipettes. A fixed current of 1 nA was chosen for the analytical characterization. The sensitivity of the GOx nanopipette achieved the highest value at 1nA for glucose. When higher current values were applied sensitivity dramatically decreased (Figure S2). This might be the result of increased electroosmotic flow at the close proximity of nanopipette walls pushing ionic species in backfilling solution out of

nanopore.³⁶ Experiments were conducted in phosphate buffer and cell growth media, specifically in sugar free DMEM, and changes in potential-response were recorded. DMEM was selected for the sensor calibration for intracellular measurements because it provides the most similar matrix (including amino acids, vitamins, inorganic salts, etc...) to cytoplasmic fluid.

Figure 3 displays the calibration curves obtained with increasing glucose concentration in PBS and glucose-free DMEM using glucose nanosensors. The sensitivity of the nanosensors was 13.89 between 0.1 and 1 mM and 2.29 mV/mM between 1 and 10 mM glucose for DMEM, and a sensitivity of 20.40 mV/mM was obtained for PBS. The coefficient of correlation (R^2) of the calibration curves were 0.9318 for PBS and 0.9055 and 0.9725 for DMEM. The bimodal distribution of the linear range in cell media could be a consequence of two sequential processes including electrophoretic flow of the substrate to the nanopipette tip and diffusion of the products from the tip. Several factors can affect this behavior, such as slow diffusion rate of glucose through the nanopore in the presence of a variety of components present in cell media and fast enzymatic conversion that concentrates the products (including gluconic acid and hydrogen peroxide) at the nanopore. To assess the effect of simple glucose addition to the bulk solution, we performed calibration after each modification step (**Figure S3**). The nanopipettes in the absence of glucose oxidase showed no significant changes in potential-response with changes in glucose concentrations. The coefficient of variation of GOx-functionalized nanopipettes was calculated to be 10.4%. To determine the specificity of the nanosensor the effect of common interferences were assessed and GOx-functionalized nanopipettes showed high specificity to glucose (**Figure S4**).

Figure 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

After the analytical characterization of the GOx-modified nanopipettes as glucose nanosensors, we used these sensors to evaluate whether intracellular free glucose levels differ between breast cancer cell and non-malignant cell lines. We have utilized MDA-MB-231, MCF-7 and human fibroblasts as cell models. MDA-MB-231 and MCF-7 are breast cancer cell lines. MDA-MB-231 is a highly aggressive metastatic breast cancer type, whereas MCF-7 is an estradiol responsive breast cancer line.⁴ These breast cancer cell lines were selected because they show differential sensitivity to drug treatment; therefore we investigated whether intracellular glucose levels were correlated with drug resistance. Human fibroblasts were used as a control to represent normal cytoplasmic conditions.²² Intracellular glucose measurements were made in multiple individual cells from human fibroblasts, MCF-7 and MDA-MB-231 using the glucose nanosensors. Our glucose nanosensors were inserted using the customized SICM setup described earlier. After the insertion, a fixed current of 1 nA was applied for 60 sec to perform the intracellular measurements.

We calculated the intracellular free glucose concentrations of individual cell using the GOx calibration curve. Each individual cell was interrogated three times to obtain an accurate reading. Micrographs in **Figure S6** were obtained during intracellular glucose measurements, and no changes in cell morphology were observed, further validating that these nanosensors do not cause physical damage to the cells. In our previous work, we have used nanopipettes to inject materials into single-cells and showed evidence that nanopipette manipulations did not cause functional damage to cells.²⁴ In order to demonstrate the viability of cells after nanosensor insertion; we have employed this approach and utilized bare quartz single-barrel nanopipettes to label cells with a fluorescence probe. Figure S7 shows a cell labeled with Rhodamine B 5 min, 5 and 24 hrs after nanopipette manipulation. The results clearly demonstrate that nanopipette

manipulations do not cause a lethal damage and cells survive. **Figure 4** summarizes the intracellular glucose levels estimated using our glucose nanosensors for human fibroblasts, MCF-7 and MDA-MB-231 cells. Six human fibroblast cells were investigated for intracellular glucose measurements (**Figure S6A**) and the average free glucose was $0.63 (\pm 0.44)$ mM (**Figure 4**). This low level is consistent with previous reports where a FRET based indirect glucose assay was employed to measure intracellular glucose levels in chinese hamster ovary (CHO) cells and found average glucose levels in a large cell population at stable growth rates of $0.4 - 1$ mM.¹⁵ These early studies, however, could not determine the cytoplasmic glucose levels of individual cells due to the use of indirect methods lacking selectivity and sensitivity at the single-cell level. Using glucose nanosensors, we were able to elucidate the metabolic heterogeneity in a population of human fibroblasts: intracellular glucose concentrations varied from 0.17 to 1.51 mM (**Figure S6**).

Figure 4

To evaluate intracellular free glucose levels in breast cancer cell lines, we applied the glucose nanosensors to MCF-7 and MDA-MB-231 cells. Intracellular glucose measurements performed on seven individual MCF-7 cells revealed an average glucose concentration of $2.69 (\pm 1.47)$ mM (**Figure 4**). The increased glucose relative to the fibroblasts confirms the hypothesized increase in glucose uptake associated with cancer cell metabolism.³⁷ Moreover, we found a wide range of glucose levels in MCF-7 cells, from 0.86 to 7.11 mM (**Figure S6B**). The average glucose level for MDA-MB-231 was estimated as $1.21 (\pm 0.21)$ mM (**Figure S6C**). This significant difference in intracellular glucose concentrations between MCF-7 and MDA-MB-231 may be due to the differential expression of glucose transporter proteins. In a recent study, MCF-7 and MDA-MB-231 cells lines were compared for their glucose regulation mechanism by studying the expression

of glucose transporters, finding that hormone responsive breast cancer cell lines, such as MCF-7, express the GLUT12 protein whereas hormone independent lines, like MDA-MB-231, do not.⁴ The expression of this transporter could be contributing to elevated intracellular glucose concentrations. In addition to the glucose transporter, the energetic requirements of different cancer cell lines may have a part in this intracellular glucose variation.³⁷ Highly invasive and metastatic cells have a fast metabolic rate; this allows glucose taken up by the cells to be quickly phosphorylated by hexokinases to supply necessary energy for proliferation.¹¹

Figure 5

The glucose levels in both cancerous and non-cancerous cells are dependent on the presence of glucose supply in the medium. To investigate how the intracellular free glucose stock changes, we exposed the cells to glucose-free media before the glucose nanosensors were inserted. Human fibroblasts that were incubated in glucose-free media showed low to no change in intracellular free glucose levels. These results suggest that the consumption of intracellular free glucose in human fibroblast is a slow metabolic activity; therefore, these cells do not need to maintain a large inner glucose stock. On the other hand, when the breast cancer cells were incubated in glucose-free media, the measured intracellular glucose levels were noticeably lower than the cells in glucose-containing media. The intracellular free glucose levels dropped 31.34% and 25.04% for MCF-7 and MDA-MB-231, respectively (**Figure 5**). These findings provide evidence for the active uptake of glucose into cancer cells. Cancer cells need a large glucose stock in order to keep their altered metabolic processes during an eventual extracellular glucose variation. Once glucose is depleted from the extracellular media, cancer cells use their internal glucose stock, which can be rapidly extinguished due to their high metabolism.

1 In summary, we present GOx-functionalized nanopipettes as glucose nanosensors that provide
2 the first measurements of intracellular free glucose at a single-cell level. The nanosensor
3 measures low micromolar concentrations of glucose with a linear range of 0.1 – 8 mM and
4 sensitivity values of 20.40 and 13.89 mV/mM for PBS and DMEM, respectively. Overall, our
5 findings demonstrate that intracellular glucose levels are dependent on the cell type. The average
6 intracellular concentration of free glucose for single human fibroblasts was found 0.63 ($\pm$ 0.44)
7 mM, whereas the intracellular concentration of free glucose for single breast cancer MCF-7 cells
8 was 2.69 ($\pm$ 1.47) mM and for MDA-MB-231 cells was between 1.21($\pm$ 0.21) mM. Intracellular
9 glucose levels in single metastatic human breast cancer cells were more than 2-fold greater than
10 non-malignant human cells. This observation is consistent with the greater need for glucose for
11 metabolic activity of cancer cells for proliferation and tissue invasion and increased level of
12 glucose transporters, such as GLUT1, GLUT2 and GLUT12 in cancer cells.

13 In conclusion, the glucose nanosensor technology provides a real time measure of metabolic
14 activity in cells that can be used to study biology and transformation of single cancer cells in
15 heterogeneous cell populations with temporal and spatial resolution. The surface chemistry
16 developed for the immobilization of the enzyme on quartz surface, in this work, can be applied
17 for the fabrication of a variety of enzymatic nanopipette-based nanobiosensor for single-cell
18 metabolic analysis. Additionally, the use of nanopipette as a sensing tool expands the limits of
19 nanobioscience by allowing a tool to get in not only a single cell but also into sub-cellular
20 entities, such as nucleus. This exciting level of resolution promises to illuminate the
21 transformation of single cancer cells in heterogeneous cell populations and shows great promise
22 for new levels of biological inquiry. Currently, efforts are undergoing for the development of
23 fully automated surface finder and sensor platform to increase the single-cell analysis throughput

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

up to 120 cells/hour. The utility of the glucose nanosensors reported here is not limited to cancer cells and can be expanded for the assessment of glucose metabolism other specialized cells and conditions, e.g., neurons in neurodegenerative states such as Parkinson’s and Alzheimer’s diseases.

Acknowledgements

This work was supported in part by grants from the National Institutes of Health [P01-35HG000205], National Institute of Neurological Disorders and Stroke [R21NS082927], CAPES and CNPq Brazilian agencies. We acknowledge Dr. Tom Yuzvinsky for image acquisition and the W.M. Keck Center for Nanoscale Optofluidics for use of the FEI Quanta 3D Dualbeam microscope.

Supporting Information

Experimental details on nanosensor fabrication. Additional sensor characterization experiments including; applied current optimization, specificity and selectivity. Details on intracellular measurements. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Notes

The authors declare no competing financial interest.




Figure 1 (A) Schematic displaying the surface modifications for the immobilization of glucose oxidase to the nanopipette tip. First, the inner surface of quartz nanopipette is coated with PLL. Then the surface is treated with glutaraldehyde to crosslink the amino group of PLL and that of glucose oxidase. (B) Electrochemical characterization of nanopipette after each modification step. Supporting electrolyte was 10 mM PBS (pH 7.0). (C) A typical SEM image of the nanopipette tip. Inset displays the tip geometry. (D) The enzymatic conversion of D-glucose to hydrogen peroxide and gluconic acid.




Figure 2 Single cell surface finding and intracellular glucose measurements using glucose nanosensor. The potential at the nanopipette tip is recorded providing both a way to assess the location of the tip relative to a cell. As the tip moves toward the cell, there is no change in potential but as it penetrates the cell, the potential is greatly increased. Typical recordings in the cell last for 60 sec. Once the nanopipette is extracted from the cell the tip potential returns to levels similar to those prior to cell insertion. This indicates the tip is not likely to have been damaged by the insertion.




Figure 3 Glucose-dependent potential-responses of glucose oxidase modified nanosensor in (A) 10 mM PBS (pH 7.0) and (B) cell media (DMEM). The bare nanopipette did not show concentration-dependent potential-response changes, demonstrating the specificity of GOx-modified nanopipette. The potential changes recorded at a fixed current of 1 nA and bandwidth of 1 kHz. The error bars represent the standard deviation for $n = 3$ replicates.




Figure 4 The box graph summarizing the average measured intracellular glucose levels of the cell lines interrogated in this work. Upper and lower bars represent the highest and the lowest glucose concentrations measured with glucose nanosensors. The boxes show the glucose intervals and the lines within the average glucose concentrations.




Figure 5 Comparison of intracellular glucose levels in human fibroblasts (F), MCF-7 and MDA-MB-231 cells in the glucose-rich (NM) and -free (SF) cell media. Different individual cells were analyzed to obtain average intracellular glucose. Error bars show the standard deviation for 5 replicate measurements.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. *Science* **2009**, 324, 1029-1033.

2. Gatenby, R. A.; Gillies, R. J. *Nat Rev Cancer* **2004**, 4, 891-899.

3. Elstrom, R. L.; Bauer, D. E.; Buzzai, M.; Karnauskas, R.; Harris, M. H.; Plas, D. R.; Zhuang, H.; Cinalli, R. M.; Alavi, A.; Rudin, C. M.; Thompson, C. B. *Cancer Res.* **2004**, 64, 3892-3899.

4. Macheda, M. L.; Rogers, S.; Best, J. D. *J. Cell. Physiol.* **2005**, 202, 654-662.

5. Godoy, A.; Ulloa, V.; Rodríguez, F.; Reinicke, K.; Yañez, A. J.; García, M. d. I. A.; Medina, R. A.; Carrasco, M.; Barberis, S.; Castro, T.; Martínez, F.; Koch, X.; Vera, J. C.; Poblete, M. T.; Figueroa, C. D.; Peruzzo, B.; Pérez, F.; Nualart, F. *J. Cell. Physiol.* **2006**, 207, 614-627.

6. Onodera, Y.; Nam, J.-M.; Bissell, M. J. *J. Clin. Invest.* **2014**, 124, 367-384.

7. Vaughn, A. E.; Deshmukh, M. *Nat Cell Biol* **2008**, 10, 1477-1483.

8. Harris, A. L. *Nat Rev Cancer* **2002**, 2, 38-47.

9. Cao, X.; Fang, L.; Gibbs, S.; Huang, Y.; Dai, Z.; Wen, P.; Zheng, X.; Sadee, W.; Sun, D. *Cancer Chemother. Pharmacol* **2007**, 59, 495-505.

10. Noch, E.; Khalili, K. *Mol. Cancer Ther* **2012**, 11, 14-23.

11. Annibaldi, A.; Widmann, C. *Curr Opin Clin Nutr Metab Care* **2010**, 13, 466-470.

12. Jansson, P. A.; Fowelin, J.; Smith, U.; Lonnroth, P. *Am J Physiol.* **1988**, 255, E218-E220.

13. Cline, G. W.; Jucker, B. M.; Trajanoski, Z.; Rennings, A. J. M.; Shulman, G. I. *Am J Physiol.* **1998**, 274, E381-E389.

14. Burt, B. M.; Humm, J. L.; Kooby, D. A.; Squire, O. D.; Mastorides, S.; Larson, S. M.; Fong, Y. *Neoplasia (New York, N.Y.)* **2001**, 3, 189-195.

15. Behjousiar, A.; Kontoravdi, C.; Polizzi, K. M. *PLoS ONE* **2012**, 7, e34512.

16. Zhang, L.; Su, F.; Buizer, S.; Kong, X.; Lee, F.; Day, K.; Tian, Y.; Meldrum, D. R. *Chem Comm* **2014**, 50, 6920-6922.

17. Lim, C. S.; Chung, C.; Kim, H. M.; An, M. J.; Tian, Y. S.; Chun, H. J.; Cho, B. R. *Chem Comm* **2012**, 48, 2122-2124.

18. Tian, Y. S.; Lee, H. Y.; Lim, C. S.; Park, J.; Kim, H. M.; Shin, Y. N.; Kim, E. S.; Jeon, H. J.; Park, S. B.; Cho, B. R. *Angew. Chem. Int. Ed. Engl.* **2009**, 48, 8027-8031.

19. Asif, M. H.; Ali, S. M. U.; Nur, O.; Willander, M.; Brännmark, C.; Strålfors, P.; Englund, U. H.; Elinder, F.; Danielsson, B. *Biosens Bioelectron* **2010**, 25, 2205-2211.

20. Abercrombie, M. *Am J Clin Pathol* **1978**, s3-12, 1-6.

21. Freitas, R. A., *Nanomedicine, volume I: basic capabilities*. Landes Bioscience Georgetown, TX: 1999.

22. Ozel, R. E.; Lohith, A.; Mak, W. H.; Pourmand, N. *RSC Adv* **2015**, 5, 52436-52443.

23. Umehara, S.; Pourmand, N.; Webb, C. D.; Davis, R. W.; Yasuda, K.; Karhanek, M. *Nano Lett* **2006**, 6, 2486-2492.

24. Adam Seger, R.; Actis, P.; Penfold, C.; Maalouf, M.; Vilozy, B.; Pourmand, N. *Nanoscale* **2012**, 4, 5843-5846.

25. Actis, P.; Maalouf, M. M.; Kim, H. J.; Lohith, A.; Vilozy, B.; Seger, R. A.; Pourmand, N. *ACS Nano* **2014**, 8, 546-553.

26. Actis, P.; Rogers, A.; Nivala, J.; Vilozy, B.; Seger, R. A.; Jejelowo, O.; Pourmand, N. *Biosens Bioelectron* **2011**, 26, 4503-4507.

27. Klenerman, D.; Korchev, Y. *Nanomedicine* **2006**, 1, 107-114.

28. Ying, L.; Bruckbauer, A.; Zhou, D.; Gorelik, J.; Shevchuk, A.; Lab, M.; Korchev, Y.; Klenerman, D. *Phys. Chem. Chem. Phys* **2005**, 7, 2859-2866.

29. Chen, C.-C.; Zhou, Y.; Baker, L. A. *Annu. Rev. Anal. Chem.* **2012**, 5, 207-228.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 30. Karhanek, M.; Kemp, J. T.; Pourmand, N.; Davis, R. W.; Webb, C. D. *Nano Lett* **2005**, 5, 403-407.
2 31. Vilozny, B.; Actis, P.; Seger, R. A.; Vallmajo-Martin, Q.; Pourmand, N. *Anal Chem* **2011**, 83, 6121-
3 6126.
4 32. Wilson, J.; Hunt, T., *Molecular biology of the cell: the problems book*. Garland Science: 2007.
5 33. Guilbault, G.; Nanjo, M. *Anal. Chim. Acta* **1975**, 78, 69-80.
6 34. Huggett, A. S. G.; Nixon, D. *The Lancet* **1957**, 270, 368-370.
7 35. Wang, J. *Electroanal* **2001**, 13, 983.
8 36. German, S. R.; Luo, L.; White, H. S.; Mega, T. L. *J. Phys. Chem. C* **2013**, 117, 703-711.
9 37. Hsu, P. P.; Sabatini, D. M. *Cell* **2008**, 134, 703-707.

10

11